Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-23T03:55:48.819Z Has data issue: false hasContentIssue false

EPA-1719 – Effectiveness of Switching to Agomelatine in Antidepressant-related Sexual Dysfunction

Published online by Cambridge University Press:  15 April 2020

A.L. Montejo
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca. Universidad de Salamanca. IBSAL., Salamanca, Spain
A. Perez Urdaniz
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca. Universidad de Salamanca, Salamanca, Spain
I. Mosqueira
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca., Salamanca, Spain
N. Prieto
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca. IBSAL, Salamanca, Spain
A. De la Rica
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca, Salamanca, Spain
M.T. Gallego
Affiliation:
Psychiatry Dpt., Hospital Universitario de Salamanca. IBSAL, Salamanca, Spain
S. Majadas
Affiliation:
Neuroscience Group., Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Antidepressants such as SSRI and SNRI are associated to sexual dysfunction (SD). Agomelatine, an antidepressant with an unique and different mechanism of action, didn’t produce SD in patients and healthy volunteeers (Montejo et al, 2010).

Objective

To evaluate the effectiveness of switching to agomelatine in patient's experiencing SD related to previous antidepressant treatment (AD-SD).

Methods

Observational prospective study of 2-6 months follow-up. Adult sexually active patients presenting AD-SD and switched to agomelatine monotherapy were included. SD was evaluated with the change at endpoint in the validated and specific questionnaire PR-Sex-DQ-SALSEX (Montejo et al, 2001).

Results

51 patients were included. All of them presented moderate to severe SD at inclusion. Previous AD treatment was an SSRI (63.4%) or SNRI (36.6%). Mean time of follow-up was 10.38 weeks (Sd: 5.20). Mean dose of agometine was 28.43 mg/day (Sd: 10.02). Sexual dysfunction (sexual interest, orgasm delay, anorgasmia and arousal problems) improved after switching to agomelatine, as shown by the significant reduction in PR-Sex-DQ-SALSEX score (global and by items) at endpoint (p<0.001, Wilcoxon test). At endpoint 44.9% of the sample had resolved their SD. Moderate-severe SD was present only in 18.4%. 13.9% discontinued agomelatine due to lack of efficacy and 9.7% because tolerability issues, specially associated to discontinuation syndrome.

Conclusions

In our sample global and every domain of SD improved significantly after switching to agomelatine, what makes it an apparent successful option to manage Antidepressant-related Sexual Dysfunction. A gradual switching is suggested in order to avoid treatment failure due to discontinuation syndrome.

Type
E05 - e-Poster Oral Session 05: Childhood and Geriatry, Depression
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.